Second death tied to experimental Alzheimer’s treatment
Jason Karlawish of the Perelman School of Medicine notes the benefits and risks of experimental Alzheimer’s drug lecanemab.
・ From Smithsonian Magazine
Jason Karlawish of the Perelman School of Medicine notes the benefits and risks of experimental Alzheimer’s drug lecanemab.
・ From Smithsonian Magazine